Keytruda pembrolizumab: Additional Phase I/II data

Data from 74 chemotherapy-naive patients with advanced EGFR- and anaplastic lymphoma kinase (ALK)-negative NSCLC in cohorts A-C of the open-label, international Phase I/II KEYNOTE-021 trial showed that 2 or 10 mg/kg IV Keytruda every 3 weeks plus various chemotherapy combinations led to a confirmed ORR of 57% and a median PFS of 10 months. Median OS has not yet been reached. Cohort A enrolled patients of any histology to receive Keytruda plus carboplatin and paclitaxel followed by maintenance Keytruda; cohort B enrolled patients of non-squamous histology to receive Keytruda plus carboplatin, paclitaxel and Avastin bevacizumab followed by maintenance Keytruda and Avastin; and cohort C enrolled patients of non-squamous histology to receive Keytruda plus carboplatin and Alimta pemetrexed followed by maintenance Keytruda and Alimta. ...